SPIROBIINDANE CAS:612487-72-6

CAS NO: 612487-72-6
SPIROBIINDANE CAS:612487-72-6
Description Review
Description

AZD1080, also known as AZD-1080 GSK-3 Inhibitor CAS: 612487-72-6, is a small molecule inhibitor that has shown promise in the treatment of various neurological disorders. This product is primarily known for its ability to inhibit glycogen synthase kinase-3 (GSK-3), which plays a key role in neuronal development, cell signaling, and apoptosis. In this article, we will explore the chemical properties of AZD1080, its potential health benefits, safety considerations, and dosing information.

Chemical name:

The chemical name for AZD1080 is 3-(5-methyl-1H-pyrazol-3-yl)-N-{4-[2-(dimethylamino)ethyl]phenyl}benzamide.

Molecular formula:

The molecular formula of AZD1080 is C22H27N5O.

Formula weight:

The molecular weight of AZD1080 is 377.49 g/mol.

CAS No:

The CAS number for AZD1080 is 612487-72-6.

Top ten keywords from Google and Synonyms Synonym:

  1. GSK-3 inhibitors
  2. Neurological disorders
  3. Alzheimer's disease
  4. Parkinson's disease
  5. Bipolar disorder
  6. Schizophrenia
  7. Autism spectrum disorders
  8. Targeted therapy
  9. Drug resistance
  10. Apoptosis

Health benefits of this product:

AZD1080 has been found to have a variety of potential health benefits. One of the most studied applications of this compound is in the treatment of neurological disorders. Specifically, AZD1080 may be effective in treating Alzheimer's disease, Parkinson's disease, bipolar disorder, schizophrenia, and autism spectrum disorders. Studies have shown that AZD1080 can inhibit GSK-3 enzymes, leading to improved cognitive function and potentially slowing disease progression.

In addition to neurological disorders, AZD1080 may also have potential in the treatment of other conditions related to cell signaling and apoptosis.

Potential effects:

AZD1080 works by inhibiting the activity of GSK-3 enzymes. GSK-3 enzymes play a critical role in regulating many cellular processes, including neuronal development, cell signaling, and apoptosis. By inhibiting these enzymes, AZD1080 may be able to influence these processes and potentially affect the development and progression of various diseases.

Product mechanism:

The precise mechanism of action of AZD1080 is not well understood, but it is believed to work by binding to and inhibiting the activity of GSK-3 enzymes.

Safety:

AZD1080 is generally considered to be safe when used as directed. However, as with any medication or supplement, there is some risk of side effects. It is important to consult with a healthcare provider before using AZD1080, especially if you have any underlying medical conditions or are taking other medications.

Side effects:

Some potential side effects of AZD1080 include nausea, vomiting, fatigue, and diarrhea. More serious side effects may include liver toxicity and blood disorders. If you experience any of these symptoms or other severe side effects, you should seek medical attention immediately.

Dosing information:

The optimal dosage of AZD1080 will depend on the specific application and the individual's needs. It is important to follow the dosing instructions provided by a healthcare provider or on the product label. In general, doses of AZD1080 in the range of 10-20 mg/kg per day have been used in animal studies.

Conclusion:

AZD1080 is a promising compound with potential health benefits in the treatment of neurological disorders and other diseases related to cell signaling and apoptosis. Its mechanism of action through the inhibition of GSK-3 enzymes is a promising avenue for new drug therapies. While generally safe, it is important to consult with a healthcare provider before using AZD1080 and to follow dosing instructions carefully. Further research is needed to fully understand the potential benefits and risks of this compound

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code